Journal of Nuclear Medicine shows that the peptide receptor radionuclide therapy 177Lu-DOTA-LM3 was able to control the progression of metastatic neuroendocrine neoplasms in 85% of patients. The radionuclide therapy did not result in serious adverse reactions and was well-tolerated by the patients, with a few achieving complete remission."/> Journal of Nuclear Medicine shows that the peptide receptor radionuclide therapy 177Lu-DOTA-LM3 was able to control the progression of metastatic neuroendocrine neoplasms in 85% of patients. The radionuclide therapy did not result in serious adverse reactions and was well-tolerated by the patients, with a few achieving complete remission."/> Radionuclide agent shows promise for neuroendocrine neoplasms

Radionuclide agent shows promise for neuroendocrine neoplasms

2021-11-24

A study published in the Journal of Nuclear Medicine shows that the peptide receptor radionuclide therapy 177Lu-DOTA-LM3 was able to control the progression of metastatic neuroendocrine neoplasms in 85% of patients. The radionuclide therapy did not result in serious adverse reactions and was well-tolerated by the patients, with a few achieving complete remission.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.